[BIO USA] 바카라 에볼루션 Biologics expands CMO client base to top 40 global pharmaceutical companies

[by Ji, Yong Jun] 바카라 에볼루션 Biologics is implementing a strategic initiative to expand its customer base by targeting the global top 40 pharmaceutical companies, leveraging its strengths in contract development and manufacturing (CDMO). Drawing on its experience from executing over 100 contract manufacturing (CMO) projects, the company aims to not only expand CMO agreements with existing clients but also attract mid-tier pharmaceutical firms, thereby extending its reach beyond the current top 20 clientele.

Kevin Sharp, Executive Vice President and Head of the Sales & Operations Department at 바카라 에볼루션 Biologics, stated at a press conference held during BIO USA in Boston on June 18 (local time), “We are broadening our service scope to proactively adapt to evolving market dynamics and meet the diverse modality needs of our clients.” He added, “Our goal is to actively expand our customer base from the current global top 20 pharmaceutical companies to include the top 40.”

In the first half of this year alone, 바카라 에볼루션 Biologics secured a total of USD 2.319 billion (approximately KRW 3.355 trillion) in orders through five new orders, representing approximately 60% of its total order volume of 2024 (KRW 5.4035 trillion). Notably, in January, the company signed a mega-contract valued at USD 1.410 billion with a major European pharmaceutical company.

바카라 에볼루션 Biologics is actively pursuing an expansion strategy aimed at the Asian market, with Japan, a country home to five of the global top 40 pharmaceutical companies, serving as a key target. Earlier this year, the company established a base in Tokyo, Japan. Moving forward, its U.S. subsidiary, 바카라 에볼루션 Biologics America (SBA), will focus on acquiring major global clients through its sales offices in New Jersey and Boston, while the Tokyo office will concentrate on cultivating prospective clients in the Japanese and Asian markets.

바카라 에볼루션 Biologics is also reinforcing its capabilities in next-generation modalities. The company is internalizing CDMO expertise across a broad spectrum of therapeutic platforms, including monoclonal antibodies (mAbs), bispecific and trispecific antibodies, messenger ribonucleic acid (mRNA), antibody-drug conjugates (ADCs), and adeno-associated viruses (AAV). In particular, in the ADC sector, 바카라 에볼루션 Biologics initiated its CMO operations based on conjugation technology earlier this year and aims to expand its production capacity for ADC drug products (DP) by 2027.

“We are strengthening the collaborative framework between our global sales offices and the Songdo headquarters in Incheon City to deliver seamless service,” Sharp stated. “While the sales team manages on-site customer engagement, the headquarters provides support through in-depth technical discussions.”

On June 16 (local time), 바카라 에볼루션 Biologics also announced the launch of ‘바카라 에볼루션 Organoids,’ a contract research organization (CRO) service platform using ‘organoids’ for drug screening applications. The company plans to initiate collaborations with clients at the early stages of drug candidate discovery, aiming to establish an early ‘lock-in’ effect (a strategy to foster long-term partnerships). “We intend to create a ‘super gap’ in the global CDMO market and proactively secure partnership opportunities with prospective clients,” Sharp emphasized.